Filter posts

BIO Calls Rebate Rule a “Significant Step Forward” for Patients

The Biotechnology Innovation Organization (BIO) this week lauded an administration proposal that would be a …

A Few Questions as PBMs Have Their Day on Capitol Hill

Tomorrow, the Senate Finance Committee will examine the role of pharmacy benefit managers (PBMs) in …

ICYMI: Dr. Ted Love explains “why drug pricing controls could impede innovation”

Risky. Costly. Time consuming. Rewarding. Those few words help describe a biopharmaceutical ecosystem where 90% …

A Helpful Spotlight on the Need for More Health Care Transparency

This week, the Trump administration addressed a problem confronting a growing number of Americans: surprise …

The Administration’s Orwellian Defense of Importing Foreign Price Controls

The Trump administration is out with a new blog post defending its plan to adopt …

Another Year, Another Misleading Insurance Company Report

Once again, Blue Cross Blue Shield is out with a report attempting to stoke fear …

Watchdog Report Reaffirms Concerns With Fail First

A new report by the Office of Inspector General at the U.S. Department of Health …

As Out-of-Pocket Costs Rise, Insurers Spend Big on Administrative Costs

It seems every week the insurance industry is busy pointing the finger at biopharmaceutical innovators …

New Report Offers “Distorted View” of Biopharma Industry

This week, the Minority Staff of the U.S. Senate Committee on Finance released a report …

Defining and Communicating Value

BIO President and CEO Jim Greenwood has defined value-based agreements as an important part of …